journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/28577702/the-role-of-patient-reported-outcome-measures-in-value-based-payment-reform
#1
Lee Squitieri, Kevin J Bozic, Andrea L Pusic
The U.S. health care system is currently experiencing profound change. Pressure to improve the quality of patient care and control costs have caused a rapid shift from traditional volume-driven fee-for-service reimbursement to value-based payment models. Under the 2015 Medicare Access and Children's Health Insurance Program Reauthorization Act, providers will be evaluated on the basis of quality and cost efficiency and ultimately receive adjusted reimbursement as per their performance. Although current performance metrics do not incorporate patient-reported outcome measures (PROMs), many wonder whether and how PROMs will eventually fit into value-based payment reform...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577701/challenges-of-developing-an-observable-parent-reported-measure-a-qualitative-study-of-functional-impact-of-adhd-in-children
#2
Louis S Matza, Mary Kay Margolis, Linda S Deal, Kimberly F Farrand, M Haim Erder
BACKGROUND: Informant-reported outcome measures, usually completed by parents, are often administered in pediatric clinical trials with the intention of collecting data to support claims in a medical product label. Recently, there has been an emphasis on limiting these measures to observable content, as recommended in the US Food and Drug Administration guidance on patient-reported outcomes. This qualitative study explores the concept of observability using the example of childhood attention deficit/hyperactivity disorder (ADHD)...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577700/value-for-money-in-h1n1-influenza-a-systematic-review-of-the-cost-effectiveness-of-pandemic-interventions
#3
REVIEW
Hélène Pasquini-Descomps, Nathalie Brender, David Maradan
BACKGROUND: The 2009 A/H1N1 influenza pandemic generated additional data and triggered new studies that opened debate over the optimal strategy for handling a pandemic. The lessons-learned documents from the World Health Organization show the need for a cost estimation of the pandemic response during the risk-assessment phase. Several years after the crisis, what conclusions can we draw from this field of research? OBJECTIVE: The main objective of this article was to provide an analysis of the studies that present cost-effectiveness or cost-benefit analyses for A/H1N1 pandemic interventions since 2009 and to identify which measures seem most cost-effective...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577699/budget-impact-analysis-of-against-colorectal-cancer-in-our-neighborhoods-accion-a-successful-community-based-colorectal-cancer-screening-program-for-a-medically-underserved-minority-population
#4
Bumyang Kim, David R Lairson, Tong Han Chung, Junghyun Kim, Navkiran K Shokar
OBJECTIVES: Given the uncertain cost of delivering community-based cancer screening programs, we developed a Markov simulation model to project the budget impact of implementing a comprehensive colorectal cancer (CRC) prevention program compared with the status quo. METHODS: The study modeled the impacts on the costs of clinical services, materials, and staff expenditures for recruitment, education, fecal immunochemical testing (FIT), colonoscopy, follow-up, navigation, and initial treatment...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577698/eliciting-preferences-for-clinical-follow-up-in-patients-with-head-and-neck-cancer-using-best-worst-scaling
#5
Michela Meregaglia, John Cairns, Salvatore Alfieri, Federica Favales, Daniela Mazzitelli, Ester Orlandi, Lisa Licitra, Paolo Bossi
OBJECTIVES: There are no commonly accepted standards for monitoring patients treated for head and neck cancer. The aim of this study was to assess patients' preferences for different aspects of follow-up. METHODS: A best-worst survey was conducted in a sample of head and neck cancer patients in clinical follow-up at the National Cancer Institute (Milan, Italy). Conditional logit regression with choice as the dependent variable was run to analyse the data. A covariate-adjusted analysis was performed in order to identify socio-demographic and clinical factors related to the selection of best-worst items...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577697/economic-impacts-of-the-generic-drug-user-fee-act-fee-structure
#6
Ke Dong, Garth Boehm, Qiang Zheng
BACKGROUND: A Food and Drug Administration (FDA) Generic Drug User system, Generic Drug User Fee Amendment of 2012 (GDUFA), started October 1, 2012, and has been in place for over 3 years. There is controversy about the GDUFA fee structure but no analysis of GDUFA data that we could find. OBJECTIVE: To look at the economic impact of the GDUFA fee structure. METHODS: We compared the structure of GDUFA with that of other FDA Human Drug User fees...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577696/the-type-and-impact-of-evidence-review-group-exploratory-analyses-in-the-nice-single-technology-appraisal-process
#7
Christopher Carroll, Eva Kaltenthaler, Daniel Hill-McManus, Alison Scope, Michael Holmes, Stephen Rice, Micah Rose, Paul Tappenden, Nerys Woolacott
BACKGROUND: As part of the UK National Institute for Health and Care Excellence (NICE) single technology appraisal process, independent evidence review groups (ERGs) critically appraise a company's submission relating to a specific technology and indication. OBJECTIVES: To explore the type of additional exploratory analyses conducted by ERGs and their impact on the recommendations made by NICE. METHODS: The 100 most recently completed single technology appraisals with published guidance were selected for inclusion...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577695/mind-the-gap-hospitalizations-from-multiple-sources-in-a-longitudinal-study
#8
Samuel T Savitz, Sally C Stearns, Jennifer S Groves, Anna M Kucharska-Newton, Lindsay G S Bengtson, Lisa Wruck
BACKGROUND: Medicare claims and prospective studies with self-reported utilization are important sources of hospitalization data for epidemiologic and outcomes research. OBJECTIVES: To assess the concordance of Medicare claims merged with interview-based surveillance data to determine factors associated with source completeness. METHODS: The Atherosclerosis Risk in Communities (ARIC) study recruited 15,792 cohort participants aged 45 to 64 years in the period 1987 to 1989 from four communities...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577694/manual-compression-versus-vascular-closing-device-for-closing-access-puncture-site-in-femoral-left-heart-catheterization-and-percutaneous-coronary-interventions-a-retrospective-cross-sectional-comparison-of-costs-and-effects-in-inpatient-care
#9
Julia Walter, Matthias Vogl, Martin Holderried, Christian Becker, Alina Brandes, Moritz F Sinner, Wolf Rogowski, Jens Maschmann
OBJECTIVES: To compare complication rates, length of hospital stay, and resulting costs between the use of manual compression and a vascular closing device (VCD) in both diagnostic and interventional catheterization in a German university hospital setting. METHODS: A stratified analysis according to risk profiles was used to compare the risk of complications in a retrospective cross-sectional single-center study. Differences in costs and length of hospital stay were calculated using the recycled predictions method, based on regression coefficients from generalized linear models with gamma distribution...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577693/economic-consequences-and-potentially-preventable-costs-related-to-osteoporosis-in-the-netherlands
#10
REVIEW
Tom Dunnewind, Evgeni P Dvortsin, Hugo M Smeets, Rob M Konijn, Jens H J Bos, Pieter T de Boer, Joop P van den Bergh, Maarten J Postma
BACKGROUND: Osteoporosis often does not involve symptoms, and so the actual number of patients with osteoporosis is higher than the number of diagnosed individuals. This underdiagnosis results in a treatment gap. OBJECTIVES: To estimate the total health care resource use and costs related to osteoporosis in the Netherlands, explicitly including fractures, and to estimate the proportion of fracture costs that are linked to the treatment gap and might therefore be potentially preventable; to also formulate, on the basis of these findings, strategies to optimize osteoporosis care and treatment and reduce its related costs...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577692/ulcerative-colitis-treatment-patterns-and-cost-of-care
#11
Kyle D Null, Yihua Xu, Margaret K Pasquale, Chinyu Su, Amy Marren, James Harnett, Jack Mardekian, Alireza Manuchehri, Paul Healey
OBJECTIVES: To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC). METHODS: This retrospective cohort study identified the first pharmacy or medical claim for ADA or IFX (from January 1, 2007, to December 31, 2014) in patients with continuous enrollment for 6 months or more preindex and 12 months or more postindex, with one or more UC diagnosis claim 6 months pre- or postindex...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577691/economic-evaluation-of-complete-revascularization-for-patients-with-multivessel-disease-undergoing-primary-percutaneous-coronary-intervention
#12
Garry R Barton, Lisa Irvine, Marcus Flather, Gerry P McCann, Nick Curzen, Anthony H Gershlick
OBJECTIVES: To determine the cost-effectiveness of complete revascularization at index admission compared with infarct-related artery (IRA) treatment only, in patients with multivessel disease undergoing primary percutaneous coronary intervention (P-PCI) for ST-segment elevation myocardial infarction. METHODS: An economic evaluation of a multicenter randomized trial was conducted, comparing complete revascularization at index admission to IRA-only P-PCI in patients with multivessel disease (12-month follow-up)...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577690/value-of-comprehensive-hcv-treatment-among-vulnerable-high-risk-populations
#13
Gigi A Moreno, Alice Wang, Yuri Sánchez González, Oliver Díaz Espinosa, Diana K Vania, Brian R Edlin, Ronald Brookmeyer
OBJECTIVES: The objective of this study was to explore the trade-offs society and payers make when expanding treatment access to patients with chronic hepatitis C virus (HCV) infection in early stages of disease as well as to vulnerable, high-risk populations, such as people who inject drugs (PWID) and HIV-infected men who have sex with men (MSM-HIV). METHODS: A discrete time Markov model simulated HCV progression and treatment over 20 years. Population cohorts were defined by behaviors that influence the risk of HCV exposure: PWID, MSM-HIV, an overlap cohort of individuals who are both PWID and MSM-HIV, and all other adults...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28577689/the-association-between-depression-and-medication-nonpersistence-in-new-users-of-antidiabetic-drugs
#14
Carlotta Lunghi, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette
OBJECTIVES: To measure the association between depression and nonpersistence with antidiabetic drugs (ADs) among new users of oral ADs and to estimate factors associated with nonpersistence among these new users with depression. METHODS: We used administrative claims data to identify an adult cohort (≥18 years) of new oral AD users who were free of depression. We followed the patients from AD initiation until either discontinuation, ineligibility for the public drug plan, death, or the end of the study...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28408017/systematic-review-of-health-economic-impact-evaluations-of-risk-prediction-models-stop-developing-start-evaluating
#15
REVIEW
Anoukh van Giessen, Jaime Peters, Britni Wilcher, Chris Hyde, Carl Moons, Ardine de Wit, Erik Koffijberg
BACKGROUND: Although health economic evaluations (HEEs) are increasingly common for therapeutic interventions, they appear to be rare for the use of risk prediction models (PMs). OBJECTIVES: To evaluate the current state of HEEs of PMs by performing a comprehensive systematic review. METHODS: Four databases were searched for HEEs of PM-based strategies. Two reviewers independently selected eligible articles. A checklist was compiled to score items focusing on general characteristics of HEEs of PMs, model characteristics and quality of HEEs, evidence on PMs typically used in the HEEs, and the specific challenges in performing HEEs of PMs...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28408016/a-practical-anova-approach-for-uncertainty-analysis-in-population-based-disease-microsimulation-models
#16
Behnam Sharif, Hubert Wong, Aslam H Anis, Jacek A Kopec
OBJECTIVES: To provide a practical approach for calculating uncertainty intervals and variance components associated with initial-condition and dynamic-equation parameters in computationally expensive population-based disease microsimulation models. METHODS: In the proposed uncertainty analysis approach, we calculated the required computational time and the number of runs given a user-defined error bound on the variance of the grand mean. The equations for optimal sample sizes were derived by minimizing the variance of the grand mean using initial estimates for variance components...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28408015/accounting-for-cured-patients-in-cost-effectiveness-analysis
#17
Megan Othus, Aasthaa Bansal, Lisel Koepl, Samuel Wagner, Scott Ramsey
BACKGROUND: Economic evaluations often measure an intervention effect with mean overall survival (OS). Emerging types of cancer treatments offer the possibility of being "cured" in that patients can become long-term survivors whose risk of death is the same as that of a disease-free person. Describing cured and noncured patients with one shared mean value may provide a biased assessment of a therapy with a cured proportion. OBJECTIVE: The purpose of this article is to explain how to incorporate the heterogeneity from cured patients into health economic evaluation...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28408014/cost-effectiveness-thresholds-in-global-health-taking-a-multisectoral-perspective
#18
Michelle Remme, Melisa Martinez-Alvarez, Anna Vassall
Good health is a function of a range of biological, environmental, behavioral, and social factors. The consumption of quality health care services is therefore only a part of how good health is produced. Although few would argue with this, the economic framework used to allocate resources to optimize population health is applied in a way that constrains the analyst and the decision maker to health care services. This approach risks missing two critical issues: 1) multiple sectors contribute to health gain and 2) the goods and services produced by the health sector can have multiple benefits besides health...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28408013/association-of-preference-based-health-related-quality-of-life-with-weight-loss-in-obese-adults
#19
Erica Lw Lester, Raj Padwal, Sumit R Majumdar, F Ye, Daniel W Birch, Scott W Klarenbach
BACKGROUND: The obesity epidemic is linked to substantial health care resource use, reduction in workforce and home productivity, and poor health-related quality of life (HRQOL). Changes in body mass index (BMI) are associated with improvements in HRQOL; the nature of this relationship, however, has not been reliably described. OBJECTIVES: To determine the independent association between changes in BMI and change in utility-based HRQOL. METHODS: Data were prospectively collected on 500 severely obese adult patients enrolled in a single-center obesity management clinic...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28408012/comparing-generic-and-condition-specific-preference-based-measures-in-epilepsy-eq-5d-3l-and-newqol-6d
#20
COMPARATIVE STUDY
Brendan Mulhern, Joshua Pink, Donna Rowen, Simon Borghs, Thomas Butt, Dyfrig Hughes, Antony Marson, John Brazier
BACKGROUND: There is debate about the psychometric characteristics of the three-level EuroQol five-dimensional questionnaire (EQ-5D-3L) for use in epilepsy. In response to the concerns, an epilepsy-specific preference-based measure (NEWQOL-6D) was developed. The psychometric characteristics of the NEWQOL-6D, however, have not been assessed. OBJECTIVES: To investigate the validity and responsiveness of the EQ-5D-3L and the Quality of Life in Newly Diagnosed Epilepsy Instrument-six dimensions (NEWQOL-6D) for use in the assessment of treatments for newly diagnosed focal epilepsy...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"